Racial, Ethnic Disparities in Buprenorphine, Naltrexone Prescriptions During COVID-19

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 1, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.14765?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060122

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The findings of this analysis suggest that the COVID-19 pandemic may have been associated with worsened disparities in filled buprenorphine and naltrexone prescriptions for opioid use disorder among members of racial and ethnic minority groups compared with white patients.

Authors: Sumedha Gupta, Ph.D., of Indiana University-Purdue University Indianapolis, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2022.14765)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.